Norris Perne & French LLP MI raised its position in Novartis AG (NYSE:NVS) by 1.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 132,022 shares of the company’s stock after acquiring an additional 2,358 shares during the quarter. Novartis accounts for about 1.8% of Norris Perne & French LLP MI’s investment portfolio, making the stock its 19th largest holding. Norris Perne & French LLP MI’s holdings in Novartis were worth $11,329,000 at the end of the most recent reporting period.
A number of other large investors have also recently modified their holdings of NVS. Carroll Financial Associates Inc. lifted its stake in Novartis by 3.2% in the fourth quarter. Carroll Financial Associates Inc. now owns 4,760 shares of the company’s stock valued at $404,000 after buying an additional 149 shares during the last quarter. Landmark Bank raised its stake in shares of Novartis by 4.6% during the fourth quarter. Landmark Bank now owns 4,276 shares of the company’s stock valued at $367,000 after purchasing an additional 188 shares in the last quarter. Cornerstone Advisors Inc. raised its stake in shares of Novartis by 40.4% during the fourth quarter. Cornerstone Advisors Inc. now owns 705 shares of the company’s stock valued at $60,000 after purchasing an additional 203 shares in the last quarter. Garde Capital Inc. raised its stake in shares of Novartis by 2.8% during the third quarter. Garde Capital Inc. now owns 7,715 shares of the company’s stock valued at $673,000 after purchasing an additional 210 shares in the last quarter. Finally, Davis R M Inc. raised its stake in shares of Novartis by 9.6% during the fourth quarter. Davis R M Inc. now owns 2,550 shares of the company’s stock valued at $219,000 after purchasing an additional 224 shares in the last quarter. 10.99% of the stock is owned by institutional investors.
Shares of NVS opened at $88.83 on Thursday. The stock has a market capitalization of $204.67 billion, a P/E ratio of 17.45, a P/E/G ratio of 1.93 and a beta of 0.69. Novartis AG has a 1-year low of $72.30 and a 1-year high of $92.39. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.97 and a current ratio of 1.20.
Novartis (NYSE:NVS) last released its earnings results on Wednesday, January 30th. The company reported $1.24 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.33 by ($0.09). Novartis had a net margin of 24.30% and a return on equity of 15.66%. The business had revenue of $13.27 billion for the quarter, compared to analysts’ expectations of $13.33 billion. During the same period last year, the firm earned $1.21 EPS. The company’s revenue was up 2.7% compared to the same quarter last year. As a group, equities analysts forecast that Novartis AG will post 5.43 EPS for the current year.
The firm also recently announced an annual dividend, which will be paid on Wednesday, March 13th. Shareholders of record on Tuesday, March 5th will be paid a dividend of $2.8646 per share. This represents a yield of 3.27%. The ex-dividend date is Monday, March 4th. This is a boost from Novartis’s previous annual dividend of $2.33. Novartis’s payout ratio is 37.52%.
A number of equities research analysts recently weighed in on the stock. Wolfe Research began coverage on shares of Novartis in a research note on Tuesday, October 23rd. They set an “outperform” rating on the stock. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis in a research report on Tuesday, November 6th. Barclays cut shares of Novartis from an “equal weight” rating to a “sell” rating in a research report on Friday, December 7th. Cowen upgraded shares of Novartis from a “market perform” rating to an “outperform” rating and set a $88.03 price target on the stock in a research report on Sunday, December 2nd. Finally, Zacks Investment Research upgraded shares of Novartis from a “hold” rating to a “buy” rating and set a $96.00 price target on the stock in a research report on Tuesday, December 18th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $90.94.
ILLEGAL ACTIVITY WARNING: This report was reported by Highlight Press and is the sole property of of Highlight Press. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://highlightpress.com/2019/02/14/norris-perne-french-llp-mi-buys-2358-shares-of-novartis-ag-nvs.html.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Recommended Story: Understanding each part of a balance sheet
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.